Journal Scans
EGFR Expression as a Predictor of Survival for First-Line Chemotherapy Plus Cetuximab in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Data From the Phase 3 FLEX Study
Chemotherapy + Cetuximab Improves Survival in EGFR-Expressing NSCLC
R Pirker, JR Pereira, J von Pawel, KJ O'Byrne
Yes
20120001
2012 Jan 1
Lancet Oncol
EGFR Expression as a Predictor of Survival for First-Line Chemotherapy Plus Cetuximab in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Data From the Phase 3 FLEX Study
Lancet Oncol. 2012 Jan 1;[Epub Ahead of Print], R Pirker, JR Pereira, J von Pawel, KJ O'Byrne
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
Abstract
Background: Findings from the phase 3 First-Line ErbituX in lung cancer (FLEX) study showed that the addition of cetuximab to first-line chemotherapy significantly improved overall survival compared with chemotherapy alone (hazard ratio [HR] 0·871, 95% CI 0·762—0·996; p=0·044) in patients with advanced non-small-cell lung cancer (NSCLC). To define patients benefiting most from cetuximab, we studied the association of tumour EGFR expression level with clinical outcome in FLEX study patients.Methods:...
